Oriva is developing innovative medicines for chronic gynaecological diseases and is backed by pre-seed financing from Asabys Partners’ Sabadell Asabys II fund Dr Arbat brings over 25 years’ pharma industry experience, including roles in women’s health at Bayer and Organon Oriva’s lead asset, ORV-362 – a non-hormonal, disease-modifying, first-in-class therapy for endometriosis – is already […]
FB301 was safe and well tolerated in healthy female subjects, with all primary and secondary endpoints met Clinically meaningful microbiome modulation observed, including significant improvement up to 6-month follow-up Results support progression into Phase 2, with FDA IND clearance granted in the US and CTA approved in Germany Copenhagen, Denmark and Boston, Massachusetts, 16 April […]
Over 30 years ago, the International Day of Action for Women’s Health was established by women’s rights activists to speak out and raise awareness of reproductive, sexual and maternal health issues faced by women globally. Today, the awareness day is still observed and aims to strive towards a holistic, women-centric and rights-based approach to […]
Stress urinary incontinence (SUI) is a common and debilitating problem for many women, particularly after childbirth or in later years. Yet despite this treatment options are limited, held back by a lack of research into medical products focused on women’s health. But one biotech, Versameb, hopes to change this with a novel mRNA therapy that […]
